Atherectomy Devices Market Size, Share & Trends Analysis Report By Type (Excisional Atherectomy, Laser Ablation Atherectomy, Orbital Atherectomy, Rotational Atherectomy), By Application (Coronary Artery Disease, Peripheral Arterial Disease, Others), By End-User (Hospitals, Ambulatory Surgery Centres, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2025-2033

Atherectomy Devices Market Insights

The global atherectomy devices market size was valued at USD 1,054.6 million in 2024 and is projected to grow from USD 1,153.6 million in 2025 to reach USD 1,945.0 million by 2033, exhibiting a CAGR of 6.7% during the forecast period (2025-2033).

Atherectomy devices are medical tools used to remove or break up plaque that has built up inside blood vessels, particularly in cases of peripheral artery disease (PAD) and coronary artery disease (CAD). These devices are commonly used during atherectomy procedures, which aim to restore blood flow by clearing blocked or narrowed arteries.

The global market is experiencing significant growth, driven by advancements in minimally invasive procedures and technological innovations in vascular intervention. The increasing adoption of rotational, directional, orbital, and laser atherectomy devices is reshaping the industry by offering precise plaque removal, reduced procedural complications, and improved patient outcomes.

Moreover, the integration of robotic-assisted systems, artificial intelligence-driven imaging, and drug-coated balloon (DCB) combination therapies is enhancing procedural efficiency and long-term success rates. The global market is also witnessing a shift toward outpatient and ASCs, driven by cost-effectiveness, shorter hospital stays, and the growing preference for same-day procedures.

Primary Key Trends

Integration of AI & robotics in vascular surgery

The integration of artificial intelligence (AI) and robotics is revolutionizing atherectomy procedures, enhancing surgical precision, improving efficiency, and significantly boosting patient outcomes. AI-driven imaging technologies, robotic-assisted interventions, and automated navigation systems are refining surgical accuracy and reducing procedural risks, making procedures more reliable and less invasive.

• For example, in September 2022, Corindus, a Siemens Healthineers company, introduced advancements in its CorPath GRX robotic system, designed for peripheral vascular interventions. This system enables robotic-assisted atherectomy, improving procedural precision, minimizing radiation exposure for physicians, and enhancing patient safety and outcomes.

The continuous integration of AI and robotic technology into atherectomy devices is expected to lead to improved clinical results, making procedures safer, more effective, and less prone to complications.

Growing use of drug-coated balloons in combination therapies

The increasing use of drug-coated balloons (DCBs) in combination therapies is emerging as a key trend in the atherectomy devices market. DCBs deliver antiproliferative drugs to the arterial walls, reducing restenosis and improving long-term outcomes when used alongside atherectomy procedures. This combination enhances lesion preparation, optimizes drug absorption, and minimizes the need for stents.

• For instance, in December 2024, a study published by the National Library of Medicine found that combining Rotarex-S rotational atherectomy with DCB angioplasty for femoropopliteal ISR achieved an 86.7% 12-month patency rate and a 7.9% TLR rate, highlighting its safety and efficacy while recommending larger trials for validation.

Such integration of DCBs with atherectomy procedures is shaping the future of vascular interventions, offering a promising approach for improved patient outcomes and long-term arterial patency.

Atherectomy Devices Market Driving Factors

Rising incidence of cardiovascular diseases

The increasing prevalence of cardiovascular diseases (CVDs), particularly peripheral artery disease (PAD) and coronary artery disease (CAD), is a major driver of the atherectomy devices market. Factors such as sedentary lifestyles, unhealthy diets, smoking, and the growing prevalence of diabetes are contributing to a larger patient pool requiring arterial plaque removal procedures.

• For example, in June 2023, the American Heart Association (AHA) reported a significant rise in PAD cases, estimating that over 200 million people worldwide are affected. This surge underscores the increasing demand for advanced atherectomy interventions to address arterial blockages effectively.

As the burden of cardiovascular diseases continues to rise globally, the demand for innovative atherectomy devices is expected to grow.

Increasing preference for outpatient and ambulatory care

The increasing preference for outpatient and ambulatory care settings is transforming the market, driven by the need for cost-effective, efficient, and patient-friendly treatment options. Minimally invasive atherectomy procedures are well-suited for ambulatory surgery centers (ASCs), allowing for shorter hospital stays, reduced healthcare costs, and quicker patient recovery.

• For instance, in February 2024, the American College of Cardiology (ACC) launched a new registry to provide data-driven insights into cardiac procedures performed in ASCs. This initiative reflects the rising shifts in vascular interventions, including atherectomy procedures, from traditional hospital settings to ASCs, enabling better workflow integration, improved patient outcomes, and cost efficiency.

This shift is expected to drive market growth as healthcare providers increasingly perform atherectomy procedures in ASCs, enhancing patient access, optimizing resource utilization, and improving overall treatment efficiency.

Market Restraining Factors

High cost of atherectomy devices and procedures

The high cost of atherectomy devices and procedures remains a major barrier to market expansion, particularly in low- and middle-income regions. Advanced atherectomy systems require significant investment, with high procurement and maintenance costs that strain healthcare budgets. Moreover, procedural expenses—including hospital stays, imaging, physician fees, and post-procedure care—further escalate the financial burden on patients.

Many healthcare facilities, especially in developing regions, struggle to adopt these technologies due to budget constraints and limited insurance coverage for atherectomy procedures. The cost factor not only restricts accessibility but also slows the adoption of newer, more effective technologies, hindering market growth despite the increasing prevalence of peripheral artery disease and rising demand for minimally invasive interventions.

Market Opportunity

Innovations in next-gen atherectomy devices

The development of next-generation atherectomy devices presents a significant opportunity in the market. These advanced devices incorporate AI-driven navigation, real-time imaging, and bioabsorbable materials to enhance precision, safety, and long-term effectiveness. Innovations such as laser-assisted and hybrid atherectomy systems are expanding treatment options for complex arterial lesions.

• For instance, in March 2024, a study published in the National Library of Medicine highlighted a multifunctional atherectomy device for iliac and popliteal artery occlusions in PAOD patients. The device combines atherectomy, thrombectomy, and transit functions, reducing costs. Positive outcomes were reported, with a call for multicenter studies to validate efficacy.

These advancements not only enhance patient outcomes but also drive cost-effective treatment solutions, increasing the adoption of atherectomy procedures worldwide.

Regional Insights

North America: Dominant region with 41.15% market share

North America holds the dominant position in the global atherectomy devices market, driven by the high prevalence of peripheral artery disease and the strong adoption of advanced vascular interventions. The region benefits from substantial R&D investments, a well-established healthcare infrastructure, and favorable reimbursement policies that encourage the use of atherectomy procedures.

Moreover, the presence of key market players and continuous technological advancements, such as AI-integrated atherectomy systems and robotic-assisted interventions, further accelerate market growth. Rising awareness about minimally invasive procedures and increased screening programs for CVD also contribute to the expanding market.

Asia Pacific: Fastest growing region with the highest market CAGR

Asia-Pacific is projected to experience the fastest growth, driven by increasing cases of PAD, rising healthcare expenditure, and improving access to advanced medical treatments. Rapid urbanization, an aging population, and a growing burden of diabetes and cardiovascular diseases are fueling demand for effective vascular interventions. Government initiatives to enhance healthcare infrastructure, coupled with increasing investments in minimally invasive surgical techniques, are supporting market expansion. Moreover, the growing presence of medical device manufacturers in emerging economies such as China and India is boosting product availability, further driving the adoption of atherectomy devices in the region.

Country Insights

• U.S. - The U.S. dominates the atherectomy devices industry due to high investments in R&D, an increasing number of clinical trials, and a strong regulatory framework supporting medical advancements. In November 2024, Royal Philips launched the U.S. THOR IDE clinical trial to evaluate its dual-function laser atherectomy and intravascular lithotripsy catheter, simplifying PAD treatment by integrating two therapies into one. This innovation enhances procedural efficiency and improves patient outcomes, driving market growth.
• Germany- Germany is one of the largest atherectomy device markets in Europe, driven by a high prevalence of peripheral artery disease (PAD) and the widespread adoption of minimally invasive procedures. The country’s well-established regulatory framework and favorable reimbursement policies encourage hospitals and specialized clinics to adopt cutting-edge atherectomy technologies. Moreover, strong collaborations between research institutions and medical device manufacturers contribute to continuous innovation, further propelling market expansion.
• Canada- Canada’s market for atherectomy devices is growing due to the rising incidence of PAD and coronary artery disease (CAD). Favorable reimbursement policies, strong government support for medical technology, and a well-established healthcare system are key drivers. Moreover, ongoing clinical trials and collaborations between medical institutions and device manufacturers are accelerating innovation. These factors, along with increased awareness of minimally invasive procedures, are contributing to the widespread adoption of atherectomy devices in Canada.
• India – India is experiencing significant growth in the atherectomy devices market, driven by increasing healthcare investments and facility expansions. In December 2024, the Jayadeva Institute of Cardiology and Research Institute inaugurated a new branch in Karnataka, enhancing cardiovascular healthcare accessibility. The rising burden of diabetes and PAD, along with government initiatives to improve cardiac care, is fueling demand for atherectomy procedures, making India a rapidly expanding market for vascular interventions.
• China: China's market for atherectomy devices is expanding due to the rising prevalence of PAD, increasing healthcare expenditure, and rapid advancements in medical technology. Government-led initiatives to enhance healthcare infrastructure and the growing adoption of minimally invasive procedures are pushing growth. Moreover, the presence of domestic and international medical device manufacturers is improving access to innovative atherectomy solutions, making China a key player.
• Japan- Japan is witnessing significant growth in the market, driven by strong R&D investments and increasing clinical trials. In January 2023, Cardiovascular Systems Inc. (CSI) initiated the KAIZEN clinical study to assess its Diamondback 360 peripheral orbital atherectomy system (OAS) for treating calcified plaque in PAD patients. The study aims to support regulatory approval in Japan, highlighting the country’s commitment to advancing vascular interventions and improving patient outcomes.

Segmentation Analysis

The global atherectomy devices market is segmented into type, application, and end-user.

By Type

Rotational atherectomy systems dominate the global atherectomy devices market due to their superior efficacy in treating heavily calcified arterial lesions. These systems offer precise plaque removal while minimizing vessel trauma, making them highly effective for complex cases of peripheral and coronary artery disease. Their ability to improve lumen patency, optimize stent deployment, and reduce procedural complications has positioned them as the preferred choice among interventional cardiologists and vascular surgeons, driving their widespread adoption in advanced vascular interventions.

By Application

Peripheral arterial disease (PAD) holds the largest market share in the atherectomy devices industry, driven by its high global prevalence and rising incidence. Contributing factors such as diabetes, hypertension, smoking, and obesity have expanded the patient pool, requiring atherectomy procedures. These interventions play a critical role in restoring blood flow, preventing amputations, and improving overall vascular health. As minimally invasive treatments gain traction, the demand for atherectomy devices in PAD management continues to rise, supporting market growth.

By End-User

Hospitals remain the leading end-users of atherectomy devices, owing to their well-equipped infrastructure, skilled medical professionals, and high patient influx for vascular procedures. As centers for advanced cardiovascular care, hospitals provide comprehensive treatment options, including complex atherectomy interventions for both peripheral and coronary artery diseases. The availability of cutting-edge imaging technologies, post-procedure monitoring, and emergency care further reinforces hospitals as the preferred setting for atherectomy treatments, ensuring continued market dominance.

Company Market Share

The key players in the global atherectomy devices market are increasingly focusing on adopting various business strategies, such as strategic collaborations, product approvals, acquisitions, and product launches, to gain a competitive edge and expand their market presence. These companies are forming alliances with healthcare providers, academic institutions, and research organizations to accelerate innovation and improve the accessibility of their products.

RA Medical: An emerging player in the market

RA Medical is a medical technology company specializing in laser-based vascular and dermatological treatments. In the market, the company developed the DABRA excimer laser system, designed for minimally invasive plaque removal in peripheral artery disease (PAD).

Recent developments by RA Medical:

• In March 2022, RA Medical announced the enrolment of 100 subjects in its pivotal clinical study evaluating the DABRA excimer laser system as an atherectomy device for treating peripheral arterial disease (PAD). The study, cleared to enroll up to 125 subjects, aims to assess the system's safety and effectiveness in plaque removal, supporting its regulatory pathway for atherectomy indications.

Recent Developments

• November 2024 – Philips announced the enrollment of the first patient in the U.S. THOR IDE clinical trial, evaluating a combined laser atherectomy and intravascular lithotripsy catheter. This device aims to simplify peripheral artery disease (PAD) treatment by integrating two therapies into a single procedure, potentially reducing procedural complexity and improving patient outcomes.
• April 2024 – Otsuka Medical Devices Co., Ltd. announced a definitive agreement to transfer the distribution of the Diamondback 360 Coronary Orbital Atherectomy System (OAS) in Japan to Abbott Medical Japan LLC. This strategic move is expected to expand the market reach of the Diamondback 360 system in Japan, leveraging Abbott's established distribution network and expertise in cardiovascular interventions.

Analyst Opinion

As per our analyst, the global atherectomy devices market is poised for significant growth, driven by the increasing prevalence of PAD and CAD, along with the growing adoption of minimally invasive procedures. Innovations, such as robotic-assisted atherectomy, laser-based systems, and AI-driven imaging, are improving procedural accuracy, enhancing patient outcomes, and reducing complications.

Furthermore, the integration of drug-coated balloons (DCBs) with atherectomy procedures is improving long-term efficacy by minimizing restenosis and enhancing arterial patency. Despite these advancements, the market faces challenges such as high device costs, limited reimbursement coverage, and the need for specialized training.

However, the rising demand in emerging markets, particularly in Asia-Pacific, presents substantial growth opportunities. Increased healthcare investments, rising cardiovascular disease burden, and better access to advanced medical technologies will likely overcome these challenges and drive sustained market expansion.